Before PSM | After PSM | OR/regression coefficiente (95%CI) | |||||
---|---|---|---|---|---|---|---|
Non-ILE group (n = 41,819) | ILE group (n = 19,618) | Non-ILE group (n = 19,602) | ILE group (n = 19,602) | p-value | Unadjusted | Adjustedf | |
Primary endpoint | |||||||
In-hospital mortality | 11,712 (28.0) | 3976 (20.3) | 5272 (26.9) | 3972 (20.3) | < 0.001c | 0.69 (0.66 to 0.72) | 0.71 (0.68 to 0.75) |
Secondary endpoint | |||||||
IV catheter infection | 378 (0.9) | 213 (1.1) | 178 (0.9) | 213 (1.1) | 0.08c | 1.20 (0.98 to 1.46) | 1.05 (0.85 to 1.29) |
Deteriorated ADLa | 3054 (12.0) | 1458 (10.8) | 1541 (12.5) | 1456 (10.8) | < 0.001c | 0.85 (0.79 to 0.92) | 0.88 (0.81 to 0.95) |
LOSb, mean (SD), days | 44.2 (39.1) | 42.3 (34.0) | 43.1 (36.1) | 42.3 (34.0) | 0.045d | − 0.8 (− 1.6 to 0.0) | − 1.8 (− 2.6 to − 1.0) |
Readmissionb | 2227 (7.4) | 1132 (7.2) | 1073 (7.5) | 1132 (7.2) | 0.42c | 0.96 (0.88 to 1.05) | 0.95 (0.87 to 1.04) |
Total medical cost, mean (SD), US$ | 21,084 (23,729) | 21,019 (18,486) | 21,402 (24,981) | 21,009 (18,439) | 0.08d | − 393 (− 822 to 48) | − 860 (− 1252 to − 47) |